NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise against fatty liver and scarring
Disease control CompletedThis study tested a drug called saroglitazar magnesium in 189 adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis (scarring). The goal was to see if the drug could reduce liver inflammation and scarring without making the disease worse. Participants were randomly a…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Can vitamin e tame fatty liver? new study tests the right dose
Disease control CompletedThis study tested different doses of vitamin E in 200 adults with nonalcoholic fatty liver disease (NAFLD) to find the best dose for improving liver health. Participants took vitamin E or a placebo for 24 weeks, and researchers measured changes in a key liver enzyme (ALT). The go…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug combo shows promise against advanced liver scarring
Disease control CompletedThis study tested whether two drugs—semaglutide and a combination of cilofexor and firsocostat—could improve liver scarring in people with cirrhosis caused by NASH. About 457 adults with compensated cirrhosis took part. The goal was to see if these treatments could reduce liver f…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New shot targets fatty liver disease in genetically At-Risk patients
Disease control CompletedThis study tested a drug called AZD2693 in 220 adults with a type of fatty liver disease (NASH) and liver scarring, but not cirrhosis. All participants had a specific gene variant (PNPLA3 148M) that raises their risk. The goal was to see if the drug could improve liver health by …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New drug shows promise against fatty liver disease in major trial
Disease control CompletedThis study tested a new medicine called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. The main goal was to see if the drug could reverse liver inflammation without making scarring worse, compared to a placebo. Researchers a…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
Massive Real-World study tracks fatty liver disease in over 7,000 patients
Knowledge-focused CompletedThis study followed more than 7,000 adults and children with nonalcoholic fatty liver disease (NAFLD) and its more serious form, NASH, to see how the disease progresses and how doctors treat it in real-world clinics. Researchers collected information on patient health, treatments…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:05 UTC